Fayetteville, AR, United States of America

Rohana Liyanage

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Texas A&M University System. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rohana Liyanage. Retrieved from https://idiyas.com/inventor/rohana-liyanage

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Rohana Liyanage: Innovator in Vaccine Adjuvants

Introduction

Rohana Liyanage is a notable inventor based in Fayetteville, AR (US). She has made significant contributions to the field of vaccine development, particularly through her innovative work on DNA aptamers.

Latest Patents

Liyanage holds a patent titled "CD40 Specific DNA Aptamers as Vaccine Adjuvants." This patent represents her pioneering efforts in enhancing vaccine efficacy through the use of specific DNA sequences.

Career Highlights

Currently, Rohana Liyanage is affiliated with the Texas A&M University System. Her work at this institution has allowed her to explore and develop groundbreaking technologies in immunology and vaccine research.

Collaborations

Throughout her career, Liyanage has collaborated with esteemed colleagues, including Adil Sabr Al-ogaili and Tieshan Jiang. These partnerships have further enriched her research and contributed to advancements in the field.

Conclusion

Rohana Liyanage's innovative work in vaccine adjuvants exemplifies her commitment to improving public health through scientific research. Her contributions are paving the way for future advancements in immunology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…